Dexamfetamine transdermal - Noven Pharmaceuticals

Drug Profile

Dexamfetamine transdermal - Noven Pharmaceuticals

Alternative Names: ATS; d-Amphetamine Transdermal System; d-ATS; Dextroamphetamine transdermal system - Noven; SPD-487

Latest Information Update: 03 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Noven Pharmaceuticals
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder

Most Recent Events

  • 03 Aug 2015 Phase II development for Attention-deficit hyperactivity disorder is ongoing in the USA
  • 31 Mar 2013 Noven Pharmaceuticals completes a phase IIa trial in Attention-deficit hyperactivity disorder in USA (NCT01711021)
  • 02 Oct 2012 Phase-II clinical trials in Attention-deficit hyperactivity disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top